ACTUATE THERAPEUTICS, INC. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 92/100
What the filing says
On July 15, 2026, Actuate Therapeutics filed an 8-K disclosing Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard, with potential transfer of listing. The filing document itself contains no specific details regarding which exchange issued the notice, which listing standard(s) were violated, cure periods, or remediation plans. Concrete counterparties, dollar amounts, dates of notice, or compliance metrics are absent from the available filing text.
Why this rating
Delisting is existential threat to a $42.1M public company. Loss of exchange listing severely impairs capital raising, trading liquidity, and investor access—potentially fatal for small biotech.
Extracted items
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.